Regeneron Pharmaceuticals Inc (LTS:0R2M)
$ 827.21 -6.645 (-0.8%) Market Cap: 91.15 Bil Enterprise Value: 84.05 Bil PE Ratio: 20.53 PB Ratio: 3.11 GF Score: 93/100

Regeneron Pharmaceuticals Inc at Piper Jaffray Healthcare Conference Transcript

Dec 03, 2019 / 01:00PM GMT
Release Date Price: $369.46 (+0.92%)
Christopher Joseph Raymond
Piper Jaffray Companies, Research Division - MD & Senior Research Analyst

We're going to go ahead and get started. My name is Chris Raymond. I'm a senior biotech analyst here at Piper Jaffray. It's my pleasure to introduce and kick off our 31st Annual Healthcare Conference for Piper Jaffray with Regeneron. Joining us today, we have Bob Landry, Regeneron's CFO. And also on the stage with us is Justin Holko, who heads up the IR group. So thanks for joining us.

Just to go over the format, this is a fireside chat. We try to keep this informal. So if anybody in the audience has questions, please raise your hands. We'll make sure we get them asked and answered. But first, I think we're going to go into a little bit of introduction from Bob, and then we'll kick it off. So thank you.

Robert E. Landry
Regeneron Pharmaceuticals, Inc. - Executive VP of Finance & CFO

Sure. So Chris, thanks for being here. Thanks for the invite. Regeneron's always happy to come to your event. So I've been at Regeneron for 6 years. I am the CFO.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot